Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 76Breast 11Thoracic 6Genitourinary 5Gastrointestinal 5Sarcoma 4Head & Neck 3Other solid neoplasm 2Dermatologic 2NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 43Carcinoma, Neuroendocrine 22Small Cell Lung Carcinoma 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 11Sarcoma 10Lung Neoplasms 9Thyroid Carcinoma, Anaplastic 7Thyroid Cancer, Papillary 7Stomach Neoplasms 7Pheochromocytoma 7Paraganglioma 7Head and Neck Neoplasms 7Gastro-enteropancreatic neuroendocrine tumor 7Carcinoid Tumor 7Thyroid Neoplasms 6Neoplasm Metastasis 6Colorectal Neoplasms 6Ovarian Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Diseases 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Prostatic Neoplasms 4Neuroblastoma 4Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Lung Diseases 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Fallopian Tube Neoplasms × Endocrine × Clear all
NCT05199272 2024-11-15

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

23andMe, Inc.

Phase 1/2 Active not recruiting
141 enrolled
EndocrineGenitourinaryGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡